Not applicableLooking for participantsNCT06222957What this trial is testingThe Effects of HER2 Receptor Signaling on Human Brown Fat ActivityWho this might be right forBreast Cancer Rigshospitalet, Denmark 30
Early research (Phase 1)Looking for participantsNCT06582017What this trial is testingSafety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple MyelomaWho this might be right forOvarian CancerPancreas CancerUrothelial Carcinoma+6 more Nammi Therapeutics Inc 100
Testing effectiveness (Phase 2)Ended earlyNCT03149549What this trial is testingPROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid TumorsWho this might be right forSolid Tumor, AdultBreast CancerNon Small Cell Lung Cancer+2 more CytomX Therapeutics 99
Large-scale testing (Phase 3)UnknownNCT04047758What this trial is testingPalbociclib Combined With an Aromatase Inhibitor in Breast CancerWho this might be right forBreast Cancer Shengjing Hospital 420
Early research (Phase 1)WithdrawnNCT05905341What this trial is testingStudy of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.Who this might be right forBreast CancerOvarian CancerLiposarcoma+3 more Pfizer
Large-scale testing (Phase 3)Study completedNCT02019277What this trial is testingPertuzumab and Trastuzumab Subcutaneous (SC) Treatment in Combination With a Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast CancerWho this might be right forBreast Cancer Hoffmann-La Roche 50
Early research (Phase 1)Study completedNCT04080024What this trial is testingA First-in-human Clinical Evaluation of SN132D in Patients With Breast and Pancreatic CancerWho this might be right forBreast CancerPancreas Cancer Spago Nanomedical AB 14
Testing effectiveness (Phase 2)Study completedNCT00438490What this trial is testingThe Safety and Efficacy of Recombinant Human ProlactinWho this might be right forHealthy Massachusetts General Hospital 21
Testing effectiveness (Phase 2)WithdrawnNCT01288092What this trial is testingBEZ235 Trial in Patients With HER2-(Human Epidermal Growth Factor Receptor 2 Negative) /HR+ (Hormonal Receptor Positive) Metastatic Breast CancerWho this might be right forMetastatic Breast Cancer Novartis Pharmaceuticals
Not applicableLooking for participantsNCT06672302What this trial is testingA Prospective Study to Develop and Clinically Validate an in Vitro Diagnostic Medical Device That Uses Blood to Classify Patients at High Risk for Breast CancerWho this might be right forBreast Neoplasm EXoPERT 330
Large-scale testing (Phase 3)Looking for participantsNCT07062965What this trial is testingLearn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.Who this might be right forBreast Cancer Pfizer 400
Large-scale testing (Phase 3)Looking for participantsNCT07071337What this trial is testingSKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine TherapyWho this might be right forMetastatic Breast Cancer Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 430
Large-scale testing (Phase 3)Active Not RecruitingNCT03734029What this trial is testingTrastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]Who this might be right forBreast Cancer Daiichi Sankyo 557
Early research (Phase 1)Looking for participantsNCT06400472What this trial is testingSofe-M in Participants With Selected Advanced Solid TumorsWho this might be right forOvarian NeoplasmsEndometrial NeoplasmsUterine Cervical Neoplasms+4 more Eli Lilly and Company 575
Not applicableLooking for participantsNCT05573893What this trial is testingPROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab DeruxtecanWho this might be right forBreast NeoplasmsBreast CancerNeoplasm Metastasis AstraZeneca 800
Early research (Phase 1)Ended earlyNCT06264921What this trial is testingA Study With NKT3447 for Adults With Advanced/Metastatic Solid TumorsWho this might be right forSolid TumorSolid Tumor, AdultAdvanced Solid Tumor+26 more NiKang Therapeutics, Inc. 23
Not applicableStudy completedNCT01271738What this trial is testingEvaluating and Comparing Two Surgical Methods for Treatment of Early Stage Breast CancerWho this might be right forBreast NeoplasmsBreast CancerBreast Tumors+4 more Emory University 79
Testing effectiveness (Phase 2)Study completedNCT03560531What this trial is testingZN-c5 in Subjects With Breast CancerWho this might be right forBreast Cancer Zeno Alpha Inc. 181
Testing effectiveness (Phase 2)Ended earlyNCT02753595What this trial is testingStudy of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)Who this might be right forMetastatic Breast Cancer Eisai Inc. 25
Not applicableStudy completedNCT01931644What this trial is testingAt-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic ConditionsWho this might be right forAll Diagnosed Health ConditionsADD/ADHDAlopecia Areata+58 more Sanguine Biosciences 17,667